SCHEMBL16014353

SCHEMBL16014353

CC(=O)OCc1c(Cl)cccc1-n1ncc2cccc(F)c2c1=O

nearest known ligand 0.40

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
BTK Q06187 11/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.39
TDP1 Q9NUW8 2/20 0.38
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 1/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10201391 0.88 BTK (0.44) BTK
SCHEMBL16014489 0.87 BTK (0.42) BTK
SCHEMBL16627182 0.86 BTK (0.42) BTK
SCHEMBL611319 0.86 BTK (0.57) BTK
SCHEMBL16013570 0.84 BTK (0.46) BTK
SCHEMBL16014645 0.82 HIF1A (0.39) BTKKMT2AMEN1GAALMNA
SCHEMBL17407533 0.80 BTK (0.39) BTKLMNAALDH1A1
SCHEMBL15578691 0.77 BTK (0.53) BTK
SCHEMBL16248113 0.75 BTK (0.58) BTK
SCHEMBL12503526 0.74 BTK (0.57) BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2964627-B1 INHIBITORS OF BRUTON'S TYROSINE KINASE HOFFMANN LA ROCHE (CH) 2017-03-01 EP disclosed
EP-2964627-B1 INHIBITORS OF BRUTON'S TYROSINE KINASE HOFFMANN LA ROCHE (CH) 2017-03-01 EP disclosed
US-9556147-B2 Inhibitors of bruton's tyrosine kinase HOFFMANN-LA INC. (US) 2017-01-31 US disclosed
US-9556147-B2 Inhibitors of bruton's tyrosine kinase HOFFMANN-LA INC. (US) 2017-01-31 US disclosed
US-9556147-B2 Inhibitors of bruton's tyrosine kinase HOFFMANN-LA INC. (US) 2017-01-31 US disclosed
EP-2964627-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. Hoffmann-La Roche AG (CH) 2016-01-13 EP disclosed
US-20160002206-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE HOFFMANN-LA ROCHE INC. 2016-01-07 US disclosed
WO-2014135470-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. HOFFMANN-LA ROCHE AG (CH) 2014-09-12 WO disclosed
WO-2014135470-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. HOFFMANN-LA ROCHE AG (CH) 2014-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002206-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, SYK, LYN BTK 1/4885KMT2A 2693/4885MEN1 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.